Abstract
The leukotriene A4 hydrolase (LTA4H) is a bifunctional zinc enzyme that catalyzes the final (rate-limiting) step in the synthesis of leukotriene B4 (LTB4), which is involved in several diseases. Many pharmaceutical attempts to exploit the LTA4H/LTB4 pathway have been unsatisfactory, hence, the development of new inhibitory drugs is essential. This paper describes the generation of a quantitative structure–activity relationship (QSAR) model on a series of 50 N-alkyl glycine amides with experimentally defined IC50. In addition, the optimized molecular structures of the inhibitors were docked into the active site of the enzyme to identify the enzyme-ligand interactions and quantify the estimated free energy of binding (ΔGbind). A simple four-descriptor QSAR model with high predictive capacity was obtained. The statistic parameters of the model are: regression coefficient (Rtest) of 0.714 and a standard deviation (Stest) of 0.696. The predicted inhibitory activity of 85 new N-alkyl glycine amides compounds was obtained with this QSAR model and these compounds were docked into LTA4H. Ten of the compounds present predicted IC50 values lower than 10 nM and binding poses and affinity values similar to the natural ligand (leukotriene A4), turning them into suitable candidates for experimental assays.
Similar content being viewed by others
References
Back M, Bu DX, Branstrom R, Sheikine Y, Yan ZQ, Hansson GK (2005) Leukotriene B4 signaling through NF-{kappa}B-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci USA 102:17501–17506
Barnes PJ (2001) Future advances in COPD therapy. Respiration 68:441–448
Bernstein FC, Koetzle TF, Williams GJB, Meyer EF Jr, Brice MD, Rodgers JR, Kennard O, Shimanouchi T, Tasumi M (1977) The Protein Data Bank: a computer-based archival file for macromolecular structures. J Mol Biol 112:535–542
Çalışkan B, Banoglu E (2013) Overview of recent drug discovery approaches for new generation leukotriene A4 hydrolase inhibitors. Expert Opin Drug Discov 8:49–63
Chen X, Wang S, Wu N, Yang CS (2004) Leukotriene A4 hydrolase as a target for cancer prevention and therapy. Curr Cancer Drug Targets 4:267–283
Duchowicz PR, Castro EA, Fernandez FM, González MP (2005) A new search algorithm for QSPR/QSAR theories: normal boiling points of some organic molecules. Chem phys lett 412:376–380
Golbraikh A, Tropsha A (2002) Beware of q2! J Mol Graph Model 20:269–276
Goodarzi K, Goodarzi M, Tager AM, Luster AD, von Andrian UH (2003) Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues. Nat Immunol 4:965–973
Haeggström JZ (2004) Leukotriene A4 hydrolase/aminopeptidase, the gatekeeper of chemotactic leukotriene B4 biosynthesis. J Biol Chem 279:50639–50642
Hansch C (1990) Comprehensive drug design. Pergamon Press, New York
Jain A, Sharma R, Chaturvedi SC (2011) Structural Insight for benzimidazole as angiotensin II AT1 receptor antagonist by using molecular property and biolgogical activity correlation: Qsar approach. Int J Pharm PharmSci 3:541–546
Kirkland TA, Adler M, Bauman JG, Chen M, Haeggstrçm JZ, King B, Kochanny MJ, Liang AM, Mendoza L, Phillips GB, Thunnissen M, Trinh L, Whitlow M, Ye B, Ye H, Parkinson J, Guilford WJ (2008) Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorgan Med Chem 16:4963–4983
Mercader AG, Duchowicz PR, Fernandez FM, Castro EA (2010) Replacement method and enhanced replacement method versus the genetic algorithm approach for the selection of molecular descriptors in QSPR/QSAR theories. J Chem Inf Model 50:1542–1548
Natarajan R, Basak SC, Mills D, Kraker JJ, Hawkinsb DM (2008) Quantitative structure-activity relationship modeling of mosquito repellents using calculated descriptors. Croat Chem Acta 81:333–340
Nekoei M, Salami M, Dolatabadi M, Mohammadhosseini M (2011) A quantitative structure–activity relationship study of tetrabutylphosphonium bromide analogs as muscarinic acetylcholine receptors agonists. J Serb Chem Soc 76:1117–1127
Paz PB, Vega-Hissi EG, Estrada MR, Garro Martinez JC (2012) In silico modeling of the molecular structure and minding of leukotriene A4 into leukotriene A4 hydrolase. Chem Biol Drug Des 80:902–908
Penning TD (2001) Inhibitors of Leukotriene A4 (LTA4) hydrolase as potential anti inflammatory agents. Curr Pharm Des 7:163–179
Ramírez-Galicia G, Garduño-Juárez R, Correa-Basurto J, Deeb O (2012) Exploring QSAR for inhibitory effect a set of heterocyclic thrombin inhibitors by multilinear regression refined by artificial neural network and molecular docking simulations. J Enzym Inhib Med Chem 27:174–186
Rinaldo-Matthis A, Haeggström JZ (2010) Structures and mechanisms of enzymes in the leukotriene cascade. Biochimie 92:676–681
Rudberg PC, Tholander F, Andberg M, Thunnissen MM, Haeggström JZ (2002) Leukotriene A4 hydrolase: identification of a common carboxylate recognition site for the epoxide hydrolase and aminopeptidase substrates. J Biol Chem 279:27376–27382
Sandanayaka V, Mamat B, Mishra RK, Winger J, Krohn M, Zhou LM, Keyvan M, Enache L, Sullins D, Onua E, Zhang J, Halldorsdottir G, Sigthorsdottir H, Thorlaksdottir A, Sigthorsson G, Thorsteinnsdottir M, Davies DR, Stewart LJ, Zembower DE, Andresson T, Kiselyov AS, Singh J, Gurney ME (2010a) Discovery of 4-[(2S)-2-{[4-(4-Chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]butanoic Acid (DG-051) as a Novel Leukotriene A4 Hydrolase Inhibitor of Leukotriene B4 Biosynthesis. J Med Chem 53:573–585
Sandanayaka V, Mamat B, Mishra RK, Winger J, Krohn M, Zhou LM, Keyvan M, Enache L, Sullins D, Onua E, Zhang J, Halldorsdottir G, Sigthorsdottir H, Thorlaksdottir A, Sigthorsson G, Thorsteinnsdottir M, Davies DR, Stewart LJ, Zembower DE, Andresson T, Kiselyov AS, Singh J, Gurney ME (2010b) Discovery of 4-[(2S)-2-{[4-(4-Chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]butanoic Acid (DG-051) as a Novel Leukotriene A4 Hydrolase Inhibitor of Leukotriene B4 Biosynthesis. J Med Chem 53:573–585
Shim YM, Paige M (2012) Leukotriene A4 hydrolase–an evolving therapeutic target. In: Khatami Mahin (ed) inflammatory diseases-immunopathology, clinical and pharmacological bases. InTech, west palm Beach, pp 254–278
Tanis VM, Bacani GM, Blevitt JM, Chrovian CC, Crawford S, De Leon A, Fourie AM, Gomez L, Grice CA, Herman K, Kearney AM, Landry-Bayle AM, Lee-Dutra A, Nelson J, Riley JP, Santillán A Jr, Wiener JJM, Xue X, Young AL (2012) Azabenzthiazole inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem Lett 22:7504–7511
Thangapandian S, John S, Sakkiah S, Lee KW (2011) Pharmacophore-based virtual screening and Bayesian model for the identification of potential human leukotriene A4 hydrolase inhibitors. Eur J Med Chem 46:1593–1603
Thangapandian S, John S, Son M, Arulalapperumal V, Lee KW (2013) Development of Predictive QSAR Model and Its Application in the Discovery of Human Leukotriene A4 Hydrolase Inhibitors. Future Med Chem 5:27–40
Thunnissen MM, Nordlund P, Haeggström JZ (2001) Crystal structure of human leukotriene A(4) hydrolase, a bifunctional enzyme in inflammation. Nat Struct Biol 8:131–135
Thunnissen MM, Andersson B, Samuelsson B, Wong CH, Haeggstrom JZ (2002) Crystal structures of leukotriene A4 hydrolase in complex with captopril and two competitive tight-binding inhibitors. J FASEB 16:1648–1650
Todeschini R, Consonni V (2009) Molecular Descriptors for Chemoinformatics. Wiley, Weinheim
Trott O, Olson AJ (2010) AutoDock VINA: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comp Chem 31:455–461
Vicente E, Duchowicz PR, Benítez D, Castro EA, Cerecettoc H, González M, Monge A (2010) Anti-T cruzi activities and QSAR studies of 3-arylquinoxaline-2-carbonitrile di-N-oxides. Bioorg Med Chem Lett 20:4831–4835
Wold S, Eriksson L (1995) Chemometrics methods in molecular design. Wiley, Weinheim
Wunder F, Tinel H, Kast R, Geerts A, Becker EM, Kolkhof P, Hutter J, Erguden J, Harter M (2010) Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT2) receptor. Br J Pharmacol 160:399–409
Ye B, Bauman J, Chen M, Davey D, Khim SK, King B, Kirkland T, Kochanny M, Liang A, Lentz D, Maya K, Mendoza L, Phillips G, Selchau V, Schlyer S, Tseng JL, Wei RG, Ye H, Parkinson J, Guilford WJ (2008) Synthesis of N-alkyl glycine amides as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem Lett 18:3891–3894
Zarei K, Atabati M (2009) QSAR study of anti-HIV activities against HIV-1 and some of their mutant strains for a group of HEPT derivatives. J Chin Chem Soc 56:206–213
Acknowledgments
This work was supported by the Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) project PIP11220100100151 and Universidad Nacional de San Luis (UNSL).
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Paz, P.B., Vega-Hissi, E.G., Andrada, M.F. et al. Quantitative structure activity relationship and binding investigation of N-alkyl glycine amides as inhibitors of Leukotriene A4 hydrolase. Med Chem Res 24, 496–504 (2015). https://doi.org/10.1007/s00044-014-1121-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00044-014-1121-y